Presentation slides 28 April 2022: Preliminary Results for the Year Ended 31 December 2021

Preliminary Results for the year ended 31 December 2021

Transforming cancer care with a liquid biopsy based on a simple blood test

Andrew Newland and Ian Griffiths

28 April 2022

LSE AIM: AGL OTCQX: ANPCY

Legal disclaimer

This presentation has been prepared by ANGLE plc (the "Company"). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions.

The presentation slides which follow this notice and the oral presentation of which it forms part (together, the "Materials") are personal to the recipient and have been prepared and issued by or on behalf of the Company. For the purposes of the remainder of this notice, the term Materials shall include the presentation, the question-and-answer session that follows the presentation, hard or electronic copies of this document and any other materials distributed at, or in connection with, the presentation. The recipient agrees to return all Materials held by it in relation to the Placing upon the Company's request.

The information and opinions contained in this presentation have not been independently verified, are provided as at the date hereof and are subject to amendment, revision and completion without notice. No person is under any obligation to update or keep current the information contained in this presentation. No representation, warranty or undertaking, express or implied, is made by the Company, its advisers or representatives, or their respective officers, employees or agents as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or the opinions contained herein. The Company, its advisers or representatives, or their respective officers, employees and agents expressly disclaim any and all liability which may be based on this presentation and any errors therein or omissions therefrom.

This presentation does not constitute or form any part of, and should not be construed as, an offer to sell, or an invitation or solicitation or recommendation to purchase, or subscribe for or underwrite or otherwise acquire any securities in the Company in any jurisdiction and does not constitute or form part of a prospectus. No part of this presentation should form the basis of, or be relied on in connection with, or act as any inducement to enter into, any contract or commitment or investment decision whatsoever. The Company's nominated adviser, Joh. Berenberg, Gossler & Co. KG (London branch) ("Berenberg") has not approved this document for the purposes of section 21 of the Financial Services and Markets Act 2000 ("FSMA") and accordingly it is a communication made only to persons who (a) fall within one or more of the exemptions from section 21 of FSMA contained in articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (which includes persons who are authorised or exempt persons within the meaning of FSMA, certain other investment professionals, high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts) and persons who are otherwise permitted by law to receive it and (b) are an "eligible counterparty" within the meaning of Article 24(2), (3) and (4) of Directive 2004/39/EC ("MiFID")) as implemented into national law of the relevant EEA state (together, the "Relevant Persons"). Any investment or investment activity to which this document relates is only available to the Relevant Persons. Persons of any other description, including those who do not have professional experience in matters relating to investments, should not rely on this document or act on its contents for any purpose whatsoever and should return it to Berenberg immediately.

This presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. If you are in any doubt in relation to these matters, you should consult your stockbroker, bank manager, solicitor, accountant, taxation adviser or other independent financial adviser (where applicable, as authorised under FSMA).

This presentation contains certain statements that are neither reported financial results nor other historical information. These statements include information with respect to the Company's financial condition, its results of operations and businesses, strategy, plans and objectives. Words such as "anticipates", "expects", "should", "intends", "plans", "believes", "outlook", "seeks", "estimates", "targets", "may", "will", "continue", "project" and similar expressions, as well as statements in the future tense, identify forward-looking statements. These forward-looking statements are not guarantees of the Company's future performance and are subject to assumptions, risks and uncertainties that could cause actual future results to differ materially from those expressed in or implied by such forward-looking statements. No statement in the Materials is intended to be nor may it be construed as a profit forecast. Many of these assumptions, risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely and include, but are not limited to, the general economic climate and market conditions, as well as specific factors including the success of the Company's and its subsidiaries' (the "Group") research and development and commercialisation strategies, the uncertainties related to regulatory clearance and the acceptance of the Group's products by customers.

For further details regarding these and other assumptions, risks and uncertainties that may affect the Group, please read the Directors' Report section including the "Principal risks and uncertainties" in the most recent Annual Report & Accounts of the Company. In addition, new factors emerge from time to time and the Company cannot assess the potential impact of any such factor on its activities or the extent to which any factor, or combination of factors, may cause actual future results to differ materially from those contained in any forward-looking statement. Except as may be required by law or regulation, the Company undertakes no obligation to update any of its forward-looking statements, which speak only as of the date of this document.

Liquid biopsy - improving patient outcomes and reducing healthcare costs

Parsortix® cassette

"ANGLE's mission is to enable personalised cancer care by providing the best sample of the patient's cancer from a simple blood test.

Product-based solution for simple, effective, affordable repeat testing of intact cells."

Andrew Newland, Chief Executive

National Cancer Institute United States

An estimated 40% of men and women will be diagnosed with cancer during their lifetime.

2021 Highlights

Significant progress against key strategic objectives

• • FDA review of De Novo Submission for Class II clearance in metastatic breast cancer response awaited - comprehensive response to AIR submitted as planned - regular and constructive dialogue with FDA

• • Clinical laboratories in the UK and United States opened ahead of plan and services business building

  • - first three pharma services customers secured

  • - post year end, two new customers and two new contracts with existing customers for further clinical trials

  • - discussions with multiple potential customers in progress

  • - United States laboratory registered with CLIA post year end

• • Ovarian cancer detection study nearing completion

  • - patient enrolment completed

  • - delayed reagents received post year end and being validated

  • - sample analysis to resume and headline results anticipated mid-year

• • Prostate cancer study design completed and discussions progressed with a major group of United States urology clinics

• • Capital raise of £20 million well supported by new and existing shareholders in UK and United States

Financial Results for the year ended 31 December 2021

2021 £'000

2020 £'000

Statement of Comprehensive Income

Revenue and grant income 1,054

Cost of sales (302)

Gross profit and grant income 752

Operating costs

Tax credit and net finance costs

841

(165)

676

(17,987)

(14,407)

2,223

2,125

Loss for the period

(15,012)

(11,606)

2021 2020

£'000 £'000

Statement of Financial Position

Trade and other receivables and R&D tax credit Inventories

Cash and short-term deposits

Property, plant and equipment and right-of-use assets Intangible assets

5,779 3,570

1,748 742

31,839 28,618 Fundraise £18.9 million (net)

4,376 2,409 July 2021

3,573 3,710

Total assets

47,315 39,049

Comments

• • Revenue increased by 33%

excluding grant income

• • Gross margin 70%

• • Planned operating expenditure £18.0 million

• • Cash position increased to £31.8 million

• R&D tax credit due £4.5m

•